Galapagos receives transparency notification and 13D filing from Tang Capital
Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV…
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated…